Agenda Details

As the new generation of AAV gene replacement, gene editing, RNA therapeutics and cell therapy generate exciting new clinical data every day they compete with the existing landscape of small molecule and biologics/antibody therapeutics. This competition along with promising new delivery methods across modalities, offer possibilities to drive ever more novel innovation on behalf of patients. This session will bring together patient, industry, regulatory and investor perspectives to explore both the promise and the current reality of old and new therapeutic modalities. These stakeholders will offer their insights on how to select among these different modalities, how mature these technologies are, the challenges faced in getting to the clinic, how patients and advocates perceive this landscape, and how these modalities may synergize with one another or with other existing modalities to improve safety and efficacy for patients.